Year All20252024202320222021202020192018201720162015201420132012201120102007 05.09.22 Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update – Topline data from revumenib (SNDX-5613) and axatilimab pivotal programs expected starting in 1H23; Company remains on track for two FDA filings in 2023 – – BEAT-AML and AUGMENT-102 trials assessing revumenib (SNDX-5613) in combination with venetoclax-azacitidine for newly diagnosed patients and Read More 05.02.22 Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022 WALTHAM, Mass. , May 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will release its first quarter 2022 financial results Read More 03.01.22 Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update - Enrollment remains on track for pivotal programs of SNDX-5613 and axatilimab; topline data expected starting in 1H23 - - Initiation of three new trials of SNDX-5613 in NPM1 and MLLr acute leukemias, including in the first-line and maintenance settings, expected in 1H22 - - Company to host Read More 03.01.22 Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer WALTHAM, Mass. , March 1, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Kate Madigan , M.D., to the role of Read More 02.28.22 Syndax Announces Participation at Two Upcoming Investor Conferences WALTHAM, Mass. , Feb. 28, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two Read More 02.22.22 Syndax to Announce Fourth Quarter and Year-end 2021 Financial Results and Host Conference Call and Webcast on March 1, 2022 WALTHAM, Mass., Feb. 22, 2022 (PRNEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will release its fourth quarter and year-end 2021 Read More 02.03.22 Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development WALTHAM, Mass. , Feb. 3, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Read More 01.20.22 Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference WALTHAM, Mass. , Jan. 20, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a Read More 01.07.22 Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference WALTHAM, Mass. , Jan. 7, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Read More 12.22.21 Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia WALTHAM, Mass. , Dec. 22, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the European Commission has granted Orphan Drug Read More 12.20.21 Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares WALTHAM, Mass. , Dec. 20, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public Read More 12.15.21 Syndax Announces Pricing of $75.3 Million Public Offering WALTHAM, Mass. , Dec. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the pricing of an underwritten public offering of 3,157,144 Read More
05.09.22 Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update – Topline data from revumenib (SNDX-5613) and axatilimab pivotal programs expected starting in 1H23; Company remains on track for two FDA filings in 2023 – – BEAT-AML and AUGMENT-102 trials assessing revumenib (SNDX-5613) in combination with venetoclax-azacitidine for newly diagnosed patients and Read More
05.02.22 Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022 WALTHAM, Mass. , May 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will release its first quarter 2022 financial results Read More
03.01.22 Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update - Enrollment remains on track for pivotal programs of SNDX-5613 and axatilimab; topline data expected starting in 1H23 - - Initiation of three new trials of SNDX-5613 in NPM1 and MLLr acute leukemias, including in the first-line and maintenance settings, expected in 1H22 - - Company to host Read More
03.01.22 Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer WALTHAM, Mass. , March 1, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Kate Madigan , M.D., to the role of Read More
02.28.22 Syndax Announces Participation at Two Upcoming Investor Conferences WALTHAM, Mass. , Feb. 28, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two Read More
02.22.22 Syndax to Announce Fourth Quarter and Year-end 2021 Financial Results and Host Conference Call and Webcast on March 1, 2022 WALTHAM, Mass., Feb. 22, 2022 (PRNEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will release its fourth quarter and year-end 2021 Read More
02.03.22 Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development WALTHAM, Mass. , Feb. 3, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Read More
01.20.22 Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference WALTHAM, Mass. , Jan. 20, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a Read More
01.07.22 Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference WALTHAM, Mass. , Jan. 7, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Read More
12.22.21 Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia WALTHAM, Mass. , Dec. 22, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the European Commission has granted Orphan Drug Read More
12.20.21 Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares WALTHAM, Mass. , Dec. 20, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public Read More
12.15.21 Syndax Announces Pricing of $75.3 Million Public Offering WALTHAM, Mass. , Dec. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the pricing of an underwritten public offering of 3,157,144 Read More